With over $60 million of investment by the provincial and federal governments, the LKSAVI occupies over 4,000 m2 of new fully equipped lab space. Furthermore, it has access to new imaging facilities, robotics to support large-scale drug and siRNA screens, as well as state-of-the-art cell-sorting equipment and cell culture.

For GMP manufacturing, the LKSAVI has established a strong collaboration with Alberta Cell Therapy Manufacturing, a GMP facility that occupies approximately 10,000 ft2 in the Li Ka Shing Centre for Health Innovation. This facility is equipped with six cleanrooms that allow for the manufacturing of GMP-grade biological products. With the AVI industry-experienced personnel along with the ability to produce high quality biological products for human use in this GMP facility, the LKSAVI is the leading, sole entity with this capacity not only in Alberta, but in all of Western Canada.

The LKSAVI is a leader in artificial intelligence (AI) for computational drug design. Our acquisition of a Blue Gene/Q from IBM, the fastest supercomputer in Canada, allows for state-of-art drug discovery targeted at various diseases currently affecting Canadians, as well as millions of people worldwide. The opportunities afforded by this infrastructure has allowed us to move drug discovery by artificial intelligence beyond viruses. This ability is strengthened by the strong partnership of the AVI with Southern Ontario Smart Computing Innovation Platform (SOSCIP), an Ontario-based collaborative research consortium, with 15-member academic institutions and IBM Canada Ltd. as the lead industrial partner.

The Li Ka Shing Applied Virology Institute and Alberta Cell Therapy Manufacturing are located in the Li Ka Shing Centre for Health Innovation at the University of Alberta.